Drugs for Duchenne Muscular Dystrophy (DMD) Market, Global Outlook and Forecast 2025-2032
The global Drugs for Duchenne Muscular Dystrophy (DMD) market size was estimated at USD 198 million in 2024 and is projected to reach USD 514.76 million by 2032, exhibiting a CAGR of 11.20% during the forecast period.
North America Drugs for Duchenne Muscular Dystrophy (DMD) market size was estimated at USD 61.97 million in 2024, at a CAGR of 9.60% during the forecast period of 2025 through 2032.
Report Overview
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
This report provides a deep insight into the global Drugs for Duchenne Muscular Dystrophy (DMD) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Duchenne Muscular Dystrophy (DMD) market in any manner.
Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
- WaVe life Science
Market Segmentation (by Type)
- Eteplirsen
- Deflazacort
- Ataluren
Market Segmentation (by Application)
- Hospitals
- Clinics
- Home Care
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
FAQs on the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market (2024–2032)
Q1: What is the market size of the Drugs for Duchenne Muscular Dystrophy (DMD) market in 2024? A: The global Drugs for DMD market was valued at approximately USD 198 million in 2024.
Q2: What is the projected market size for Drugs for Duchenne Muscular Dystrophy by 2032? A: The market is expected to grow to around USD 514.76 million by 2032.
Q3: What is the CAGR of the Drugs for DMD market during the forecast period? A: The market is forecasted to grow at a Compound Annual Growth Rate (CAGR) of 11.20% from 2024 to 2032.
Q4: What types of drugs are included in the Duchenne Muscular Dystrophy treatment market? A: This market includes:
Exon skipping therapies
Gene therapies
Steroids and corticosteroids
Anti-inflammatory and supportive drugs
Exon skipping therapies
Gene therapies
Steroids and corticosteroids
Anti-inflammatory and supportive drugs
Q5: What factors are driving the growth of the Drugs for DMD market? A: Growth is driven by:
Increasing prevalence and awareness of Duchenne Muscular Dystrophy
Advances in gene therapy and molecular medicines
Expanding pipeline of novel DMD drugs
Rising healthcare infrastructure and funding for rare diseases
Increasing prevalence and awareness of Duchenne Muscular Dystrophy
Advances in gene therapy and molecular medicines
Expanding pipeline of novel DMD drugs
Rising healthcare infrastructure and funding for rare diseases
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Drugs for Duchenne Muscular Dystrophy (DMD) Market
- Overview of the regional outlook of the Drugs for Duchenne Muscular Dystrophy (DMD) Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through PorterÂ’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Customization of the Report
- In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
- Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
- Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Duchenne Muscular Dystrophy (DMD) Market and its likely evolution in the short to mid-term, and long term.
- Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
- Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
- Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
- Chapter 9 shares the main producing countries of Drugs for Duchenne Muscular Dystrophy (DMD), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
- Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
- Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
- Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
- Chapter 13 is the main points and conclusions of the report.
Table of content
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Key Market Segments
1.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
1.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Landscape
3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Manufacturers (2019-2025)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Manufacturers (2019-2025)
3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Sales Sites, Area Served, Product Type
3.6 Drugs for Duchenne Muscular Dystrophy (DMD) M
CONTACT US:
276 5th Avenue, New York, NY 10001, United States
International: +1(646)-781-7170 / +91 8087042414
Comments
Post a Comment